Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea · Delayed Price · Currency is KRW 1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
Operating Revenue | 820.5 | 590.37 | 267.31 | 130.02 | 1,662 | - | Upgrade |
Other Revenue | - | - | - | -0 | - | - | Upgrade |
| 820.5 | 590.37 | 267.31 | 130.02 | 1,662 | - | Upgrade | |
Revenue Growth (YoY) | 144.56% | 120.85% | 105.59% | -92.18% | - | - | Upgrade |
Cost of Revenue | 249.99 | 199.88 | 90.71 | 68.11 | 38.61 | 6.98 | Upgrade |
Gross Profit | 570.51 | 390.48 | 176.6 | 61.91 | 1,624 | -6.98 | Upgrade |
Selling, General & Admin | 5,239 | 5,463 | 6,096 | 6,976 | 8,297 | 6,010 | Upgrade |
Research & Development | 5,166 | 5,645 | 9,519 | 7,931 | 3,685 | 2,884 | Upgrade |
Other Operating Expenses | 483.58 | 458.44 | 97.24 | 48.45 | 51.15 | 64.96 | Upgrade |
Operating Expenses | 12,154 | 12,893 | 16,988 | 16,218 | 12,843 | 9,379 | Upgrade |
Operating Income | -11,584 | -12,503 | -16,812 | -16,156 | -11,219 | -9,386 | Upgrade |
Interest Expense | -44.27 | -47.21 | -235.44 | -1,350 | -1,676 | -763.41 | Upgrade |
Interest & Investment Income | 293.6 | 397.04 | 617.54 | 418.58 | 91.57 | 46.19 | Upgrade |
Earnings From Equity Investments | -956.07 | -410.1 | 22.5 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 209.59 | 126.47 | 38.01 | 136.85 | 10.83 | -5.63 | Upgrade |
Other Non Operating Income (Expenses) | 1,306 | 1,330 | 567.58 | -530.02 | -3,606 | -4,015 | Upgrade |
EBT Excluding Unusual Items | -10,775 | -11,107 | -15,801 | -17,481 | -16,399 | -14,124 | Upgrade |
Gain (Loss) on Sale of Investments | -719.76 | -719.32 | -65.12 | -535.81 | 125.76 | 1,360 | Upgrade |
Gain (Loss) on Sale of Assets | 31.03 | - | 628.33 | -32.01 | 48.87 | 0.44 | Upgrade |
Asset Writedown | -363 | -363 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | 2,136 | - | - | Upgrade |
Pretax Income | -11,826 | -12,189 | -15,238 | -15,913 | -16,224 | -12,763 | Upgrade |
Income Tax Expense | 1.09 | 1.09 | 1.04 | 1.03 | 0.92 | -1,315 | Upgrade |
Earnings From Continuing Operations | -11,828 | -12,190 | -15,239 | -15,914 | -16,225 | -11,448 | Upgrade |
Minority Interest in Earnings | - | - | 4.22 | 32.95 | 13.84 | - | Upgrade |
Net Income | -11,828 | -12,190 | -15,235 | -15,881 | -16,212 | -11,448 | Upgrade |
Net Income to Common | -11,828 | -12,190 | -15,235 | -15,881 | -16,212 | -11,448 | Upgrade |
Shares Outstanding (Basic) | 28 | 28 | 28 | 24 | 21 | 101 | Upgrade |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 24 | 21 | 101 | Upgrade |
Shares Change (YoY) | 0.85% | -0.20% | 17.02% | 12.52% | -79.08% | 5.95% | Upgrade |
EPS (Basic) | -421.05 | -437.77 | -546.00 | -666.00 | -765.00 | -113.00 | Upgrade |
EPS (Diluted) | -421.05 | -437.77 | -546.00 | -666.00 | -765.00 | -113.00 | Upgrade |
Free Cash Flow | -10,429 | -9,709 | -18,220 | -13,122 | -11,134 | -8,629 | Upgrade |
Free Cash Flow Per Share | -371.28 | -348.67 | -652.96 | -550.31 | -525.41 | -85.17 | Upgrade |
Gross Margin | 69.53% | 66.14% | 66.06% | 47.62% | 97.68% | - | Upgrade |
Operating Margin | -1411.78% | -2117.82% | -6289.14% | -12425.09% | -674.87% | - | Upgrade |
Profit Margin | -1441.51% | -2064.85% | -5699.35% | -12213.85% | -975.17% | - | Upgrade |
Free Cash Flow Margin | -1271.10% | -1644.59% | -6815.87% | -10092.16% | -669.76% | - | Upgrade |
EBITDA | -10,493 | -11,351 | -15,535 | -14,893 | -10,410 | -8,966 | Upgrade |
D&A For EBITDA | 1,091 | 1,152 | 1,277 | 1,262 | 809.72 | 419.68 | Upgrade |
EBIT | -11,584 | -12,503 | -16,812 | -16,156 | -11,219 | -9,386 | Upgrade |
Advertising Expenses | - | - | 0.42 | 1.91 | - | - | Upgrade |
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.